Leoutsakos, Jeannie-Marie S., Muthen, Bengt O., Breitner, John C. S., Lyketsos, Constantine G.

Objective: We examined the effects of non-steroidal anti-inflammatory drugs on cognitive decline as a function of phase of pre-clinical Alzheimer disease.; Methods: Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer disease. We fit growth mixture models of Modified […]

Breitner, J, Baker, L, Drye, L, Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group,

Objectives: The Alzheimer’s Disease Anti-inflammatory Prevention Trial Follow-up Study (ADAPT-FS) was designed to evaluate the efficacy of naproxen and celecoxib for the primary prevention of Alzheimer’s disease (AD) several years after cessation of treatment in ADAPT.; Methods: ADAPT was a randomized, double-masked, multicenter clinical trial of naproxen or celecoxib vs placebo (1:1:1.5 assignment ratio) at […]

Breitner, John C., Baker, Laura D., Montine, Thomas J., Meinert, Curtis L., Lyketsos, Constantine G., Ashe, Karen H., Brandt, Jason, Craft, Suzanne, Evans, Denis E., Green, Robert C., Ismail, M. Saleem, Martin, Barbara K., Mullan, Michael J., Sabbagh, Marwan, Tariot, Pierre N.

Background: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer’s dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments […]

Meinert, Curtis L., McCaffrey, Lee D., Breitner, John C. S.

Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]

Schwam, Elias M., Nicholas, Timothy, Chew, Robert, Billing, Clare B., Davidson, Wendy, Ambrose, Darlene, Altstiel, Larry D.

Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]

Reckess, Gila Z., Brandt, Jason, Luis, Cheryl A., Zandi, Peter, Martin, Barbara, Breitner, John C. S.

Compared with in-person assessment methods, telephone screening for dementia and other cognitive syndromes may improve efficiency of large population studies or prevention trials. We used data from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial to compare performance of a four-test Telephone Assessment Battery (TAB) that included the Telephone Interview for Cognitive Status (TICS) to that of […]